BORTEZOMIB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Close-monitor your Competitor's Move, Request sample copy
Growing adoption of bortezomib for treating multiple myeloma
Bortezomib was the first proteasome inhibitor approved for the treatment of multiple myeloma and it marked a major breakthrough in the management of the disease. Bortezomib is a vital part of the standard treatment regimens for multiple myeloma across all stages and forms. It has demonstrated superiority over other options in improving survival rates and delaying disease progression. Due to its well-established safety profile and significant clinical benefits, bortezomib has gained widespread acceptance amongst both patients and treating physicians over the years. Moreover, availability of bortezomib as both injectable and oral formulations has further increased patient convenience and compliance. Bortezomib is now used at various stages of multiple myeloma including induction therapy, autologous stem cell transplantation, consolidation therapy and for relapsed or refractory multiple myeloma. It is often administered along with other classes of drugs like immunosuppressants to achieve better disease control and response rates. Clinicians continuously expand the scope of bortezomib therapy based on emerging clinical evidence. For example, its use as a maintenance therapy and in combination with immunomodulators are newer approved indications. The improving accessibility to sophisticated treatments and rising affordability have also played a role in augmenting the uptake of bortezomib globally. As more real-world data underpins its clinical utility, adoption is expected to scale to a wider patient pool worldwide in the future.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
